Literature DB >> 12738002

Development of a vaccine for toxoplasmosis: current status.

Girish M Bhopale1.   

Abstract

The need for a vaccine for human toxoplasmosis is briefly discussed. Recent progress in knowledge of the protective immune response generated by Toxoplasma gondii and the current status of development of a vaccine for toxoplasmosis are highlighted.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12738002     DOI： 10.1016/s1286-4579(03)00048-0

Source DB:  PubMed          Journal:  Microbes Infect        ISSN： 1286-4579            Impact factor:   2.700


  29 in total

Review 1.  Review on the identification and role of Toxoplasma gondii antigenic epitopes.

Authors:  Yanhua Wang; Guangxiang Wang; Jianping Cai; Hong Yin
Journal:  Parasitol Res       Date:  2015-11-19       Impact factor: 2.289

2.  Toxoplasma gondii microneme protein 8 (MIC8) is a potential vaccine candidate against toxoplasmosis.

Authors:  M M Liu; Z G Yuan; G H Peng; D H Zhou; X H He; C Yan; C C Yin; Y He; R Q Lin; H Q Song; X Q Zhu
Journal:  Parasitol Res       Date:  2010-02-23       Impact factor: 2.289

3.  Evaluation of the Protective Effect of Deoxyribonucleic Acid Vaccines Encoding Granule Antigen 2 and 5 Against Acute Toxoplasmosis in BALB/c Mice.

Authors:  Xiao Teng Ching; Mun Yik Fong; Yee Ling Lau
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

4.  Kinetics and phenotype of vaccine-induced CD8+ T-cell responses to Toxoplasma gondii.

Authors:  Kimberly A Jordan; Emma H Wilson; Elia D Tait; Barbara A Fox; David S Roos; David J Bzik; Florence Dzierszinski; Christopher A Hunter
Journal:  Infect Immun       Date:  2009-06-15       Impact factor: 3.441

5.  Molecular cloning, sequencing, and biological characterization of GRA4 gene of Toxoplasma gondii.

Authors:  Hira Ram; J R Rao; A K Tewari; P S Banerjee; A K Sharma
Journal:  Parasitol Res       Date:  2013-04-10       Impact factor: 2.289

6.  Toxoplasma gondii: expression and characterization of a recombinant protein containing SAG1 and GRA2 in Pichia pastoris.

Authors:  Huaiyu Zhou; Qinmin Gu; Qunli Zhao; Jiaqin Zhang; Hua Cong; Ying Li; Shenyi He
Journal:  Parasitol Res       Date:  2006-10-21       Impact factor: 2.289

7.  Production of the main surface antigen of Toxoplasma gondii in tobacco leaves and analysis of its antigenicity and immunogenicity.

Authors:  Marina Clemente; Roberto Curilovic; Alina Sassone; Alicia Zelada; Sergio O Angel; Alejandro N Mentaberry
Journal:  Mol Biotechnol       Date:  2005-05       Impact factor: 2.695

8.  Immunogenic characterization of the chimeric surface antigen 1 and 2 (SAG1/2) of Toxoplasma gondii expressed in the yeast Pichia pastoris.

Authors:  Yee Ling Lau; Girija Thiruvengadam; Wei Wei Lee; Mun Yik Fong
Journal:  Parasitol Res       Date:  2011-04-01       Impact factor: 2.289

9.  Effect of codon optimization and subcellular targeting on Toxoplasma gondii antigen SAG1 expression in tobacco leaves to use in subcutaneous and oral immunization in mice.

Authors:  Melina Laguía-Becher; Valentina Martín; Mauricio Kraemer; Mariana Corigliano; María L Yacono; Alejandra Goldman; Marina Clemente
Journal:  BMC Biotechnol       Date:  2010-07-15       Impact factor: 2.563

10.  Dietary supplementation of mannan-oligosaccharide enhances neonatal immune responses in chickens during natural exposure to Eimeria spp.

Authors:  Gabriela Gómez-Verduzco; Arturo Cortes-Cuevas; Carlos López-Coello; Ernesto Avila-González; Gerardo M Nava
Journal:  Acta Vet Scand       Date:  2009-03-19       Impact factor: 1.695
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.